AGIO
What one share of Agios Pharmaceuticals holds
Pharmaceutical Preparations
We are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives.
Agios Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.68 |
|---|---|
| Profit | −$7.01 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$6.22 |
| Cash and investments | $1.67 |
| Book value | $17.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | $7.25 | −$8.90 | $0.63 | −$5.68 | — | −$17.52 |
| 2012 | $7.38 | −$8.02 | $0.43 | −$15.00 | — | −$19.92 |
| 2013 | $1.66 | −$2.83 | $0.08 | −$3.74 | — | — |
| 2014 | $1.94 | −$1.59 | $0.07 | −$1.83 | — | $11.44 |
| 2015 | $1.58 | −$3.15 | $0.54 | −$2.59 | — | $9.16 |
| 2016 | $1.79 | −$5.07 | $0.25 | $0.73 | — | $8.49 |
| 2017 | $0.92 | −$6.75 | $0.10 | −$6.22 | — | $7.69 |
| 2018 | $1.64 | −$6.03 | $0.12 | −$5.42 | — | $11.81 |
| 2019 | $1.97 | −$6.86 | $0.20 | −$6.38 | — | $9.36 |
| 2020 | $0.00 | −$4.74 | $0.20 | −$4.42 | — | $5.77 |
| 2021 | $0.00 | $26.55 | $0.10 | −$6.83 | — | $23.78 |
| 2022 | $0.26 | −$4.23 | $0.09 | −$5.74 | — | $20.00 |
| 2023 | $0.48 | −$6.33 | $0.02 | −$5.34 | — | $14.50 |
| 2024 | $0.63 | $11.64 | $0.03 | −$6.76 | — | $26.96 |
| 2025 | $0.93 | −$7.12 | $0.07 | −$6.51 | — | $20.41 |